• LINC02870 Drives SNAIL Translation and HCC Progression via E

  2026-06-29

  This study uncovers how the long non-coding RNA LINC02870 promotes hepatocellular carcinoma (HCC) by enhancing SNAIL translation through direct interaction with EIF4G1. The findings clarify a novel oncogenic pathway and highlight the translational control exerted by lncRNAs in liver cancer progression.

• Refining In Vitro Drug Response Metrics in Breast Cancer Res

  2026-06-29

  Schwartz's dissertation redefines how in vitro assays distinguish between cancer cell growth inhibition and cell death, offering a more precise framework for evaluating anti-cancer drug efficacy. This approach has direct implications for optimizing the study of novel PARP inhibitors such as AZD2461 and improving experimental reproducibility in breast cancer research.

• HyperScript First-Strand cDNA Synthesis Kit: Advanced Workfl

  2026-06-28

  The HyperScript First-Strand cDNA Synthesis Kit offers precision reverse transcription for even the most challenging RNA templates, supporting robust PCR and qPCR workflows. Its engineered reverse transcriptase and optimized primer system empower researchers to reliably quantify low-abundance and structurally complex transcripts.

• Wnt-C59: Precision PORCN Inhibition in Cancer Research Workf

  2026-06-27

  Wnt-C59 empowers researchers with nanomolar-precision inhibition of Wnt secretion, enabling robust modeling of Wnt-driven cancer and regenerative processes. This guide translates recent advances in Wnt/β-catenin signaling, exosomal modulation, and practical troubleshooting into actionable protocols for high-impact research.

• Ouabain in Translational Cardiovascular Research: Precision,

  2026-06-26

  This thought-leadership article explores Ouabain’s mechanistic role as a selective Na+/K+-ATPase inhibitor, its strategic application in cardiovascular and cellular research, and provides actionable protocol guidance for translational scientists. Expanding on recent literature and internal resources, it bridges experimental validation with translational impact and offers a nuanced outlook for next-generation heart failure and ion transport studies.

• BRD4 Inhibition Sensitizes Cells to Ferroptosis via ROS and

  2026-06-26

  A recent study demonstrates that BRD4 inhibitors, including I-BET-762, enhance erastin-induced ferroptosis across diverse cancer cell lines by promoting ROS accumulation and suppressing FSP1 expression. These findings clarify the mechanistic interplay between BET inhibition and ferroptosis, with direct implications for designing combination therapies targeting treatment-resistant malignancies.

• Resibufogenin Blocks NLRP3 Inflammasome to Reduce Atheroscle

  2026-06-25

  This study reveals that resibufogenin (RBG) protects ApoE-/- mice from atherosclerosis by directly inhibiting NLRP3 inflammasome assembly. By impeding pro-inflammatory signaling and influencing macrophage polarization, RBG demonstrates promise as a targeted intervention for cardiovascular inflammation.

• FITC-Concanavalin A (ConA) Conjugate: Technical Application

  2026-06-25

  FITC-Concanavalin A (ConA) Conjugate addresses the need for specific, fluorescence-based detection of α-D-glucose and α-D-mannose moieties on cell surfaces, enabling efficient analysis in immunofluorescence and flow cytometry workflows. It is not suitable for non-carbohydrate-binding assays or applications outside its defined storage and stability parameters.

• Sulfo-NHS-SS-Biotin (A8005): Precision Cell Surface Labeling

  2026-06-24

  This article demonstrates the practical advantages of Sulfo-NHS-SS-Biotin (SKU A8005) for cell surface protein labeling, purification, and assay reproducibility in biomedical research. Drawing from peer-reviewed evidence and validated protocols, it addresses real-world challenges in assay design, data interpretation, and reagent selection—highlighting how A8005 delivers reliable, reversible biotinylation optimized for affinity workflows.

• Gap19: Selective Connexin 43 Hemichannel Blocker in Neuropro

  2026-06-23

  Gap19 offers precise blockade of Cx43 hemichannels, enabling high-fidelity dissection of neuroimmune and neuroglial mechanisms in cerebral ischemia and inflammatory models. Its unique selectivity and robust solubility empower researchers to target ATP release and macrophage polarization with confidence, setting a new standard for translational neuroscience workflows.

• IWR-1-endo: Precision Wnt Signaling Inhibition for Research

  2026-06-23

  IWR-1-endo stands out as a potent Wnt signaling inhibitor, enabling high-fidelity interrogation of β-catenin-driven pathways in colorectal cancer and regenerative models. This guide delivers actionable protocols, troubleshooting tips, and contextualizes use with cutting-edge morphological profiling workflows.

• WNT5a/GSK3/β-Catenin Axis Regulates FAP Adipogenesis in Musc

  2026-06-22

  This study demonstrates that the WNT5a/GSK3/β-catenin signaling pathway is a key regulator of adipogenic differentiation in skeletal muscle fibro/adipogenic progenitors (FAPs). The findings provide mechanistic insight into muscle fatty degeneration and suggest new strategies for targeting intramuscular fat accumulation in myopathies.

• DAT Neuroimaging Validates Dopaminergic Neuron Maturation in

  2026-06-22

  Goggi et al. (2020) demonstrate that dopamine transporter (DAT) PET imaging enables accurate, non-invasive assessment of human stem cell-derived dopaminergic neuron maturation in a preclinical Parkinson’s disease (PD) model. These findings pave the way for robust in vivo monitoring of cell therapy efficacy and differentiation, an essential step for translation to clinical applications.

• ATP Solution (100 mM): Reliable Workflows for Cell-Based Ass

  2026-06-21

  Optimize your cell viability and kinase reaction workflows with ATP Solution (100 mM), SKU K1043. This article addresses real lab challenges—reproducibility, purity, and compatibility—demonstrating how APExBIO’s ATP Solution ensures sensitive, high-fidelity results in modern molecular biology assays.

• miR-18a/ALOXE3 Axis Drives Glioblastoma via Ferroptosis & Mi

  2026-06-20

  The referenced study uncovers how miR-18a promotes glioblastoma progression by targeting and suppressing ALOXE3, thereby impeding ferroptosis and enhancing cell migration via 12-HETE secretion and GsPCR-PI3K-Akt activation. These findings provide new mechanistic insight into lipid metabolic reprogramming in GBM and identify the miR-18a/ALOXE3 axis as a potential therapeutic target.

15279 records 1/1019 page Next 12345 下5页 Last page